Jefferies analyst Dennis Ding notes that AstraZeneca (AZN) announced full Phase III baxdrostat data at ESC, with efficacy looking numerically worse than Mineralys Therapeutics (MLYS) but may still be viewed as “similar,” and AstraZeneca’s hyperK looking slightly worse but it’s small N. Overall, this is one of the better scenarios for Mineralys and Jefferies expects the stock to trade up Tuesday. The data should unlock BD discussions and could potentially even accelerate them given Mineralys now could technically be considered “best in class,” says the firm. Jefferies has a Hold rating on Mineralys with a price target of $15.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
- Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones
- Mineralys Therapeutics, Inc. Earnings Call Highlights
- Mineralys Therapeutics price target raised to $43 from $38 at BofA
- 3 Best Stocks to Buy Now, 8/14/2025, According to Top Analysts